Results 171 to 180 of about 1,369,571 (283)

In Silico Decoding of Nonsteroidal Mineralocorticoid Receptor Antagonist Binding: Implications for Drug Design. [PDF]

J Chem Inf Model
Pérez-Gordillo F, Carpio LE, Alvarez de la Rosa D, Martín-Martínez M.   +3 more
europepmc   +1 more source

Expression of corticoid‐regulatory genes in the gills of Atlantic salmon (Salmo salar) parr and smolt and during salinity acclimation

Journal of Fish Biology, EarlyView.
Abstract In teleost fishes, cortisol is the major corticoid and has both glucocorticoid and mineralocorticoid actions. However, how fish tissues discriminate between these distinct corticosteroid actions is unclear. In mammals, the major factors responsible for intracellular corticosteroid regulation are glucocorticoid receptors (grs) and the ...
Makoto Kusakabe, Takashi Yada, Graham Young, Amy M. Regish, Stephen D. McCormick   +4 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonists for Liver Fibrosis: Potential Mechanisms and Research Progress. [PDF]

J Clin Transl Hepatol
Zheng H, Feng Y.
europepmc   +1 more source

Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z‐Drugs: A Target Trial Emulation

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z‐drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study
Yuichiro Matsuo, Hayato Yamana, Yusuke Sasabuchi, Hiroki Matsui, Takahide Kohro, Hideo Yasunaga   +5 more
wiley   +1 more source

The impact of mineralocorticoid receptor antagonists on fat mass and fat metabolism. [PDF]

J Endocrinol Invest
Afsar B, Afsar RE, Maddukuri G.
europepmc   +1 more source

GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

Journal of Internal Medicine, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide benefits in weight reduction, glycaemic control in Type 2 diabetes, and cardiovascular and renal outcomes. Their widespread use has given rise to concerns regarding rare but potentially serious adverse events.
Peter Ueda
wiley   +1 more source

Intrarenal Hemodynamic Mechanisms of Kidney Protection by Nonsteroidal Mineralocorticoid Receptor Antagonists. [PDF]

Endocrinol Metab (Seoul)
Koh ES, Lee SY, Hao DTT, Chung S.
europepmc   +1 more source

Mineralocorticoid Receptor [PDF]

, 2020
openaire   +1 more source

Inpatient Cardiac Resynchronization Therapy During Heart Failure Hospitalization: A Distinct High‐Risk Phenotype

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The role of cardiac resynchronization therapy (CRT) during hospitalization for heart failure (HFH) is uncertain, because hospitalized patients were routinely excluded from landmark CRT trials. Despite this, CRT implantation during HFH is common.
Oliver Rees, James Dargan, Jemima Weir, Robin Ray, Giuseppe Rosano, Fadi Johura   +5 more
wiley   +1 more source

Mineralocorticoid receptor signaling in GABAergic neurons regulates stress-induced cognitive flexibility. [PDF]

Neurobiol Stress
Yang H, Kovarova V, Godunova A, Narayan S, van Doeselaar L, Menegaz D, Eder M, Lopez JP, Deussing JM, Schmidt MV.   +9 more
europepmc   +1 more source